Q2 2026 Revvity Inc Earnings Call Transcript
Key Points
- Revvity Inc (RVTY) delivered strong Q2 results with 3% pro forma organic growth, exceeding the high end of expectations.
- The company raised its full-year guidance for organic growth, adjusted operating margin, and adjusted EPS due to stronger performance and improved optimism.
- Diagnostics segment showed exceptional performance with 11% organic growth, driven by broad-based strength in reproductive health and immunodiagnostics.
- Demand for high-content screening instruments, particularly the Opera Phenix OptIQ, remains robust with double-digit growth and accelerating order velocity.
- The company is seeing tangible signs of AI-driven demand from both traditional and nontraditional customers, positioning it well for future growth.
- Life Sciences segment experienced a 3% organic decline in Q2, primarily due to a 20% drop in the Signals software business.
- The company faced continued latent TB pressures, impacting immunodiagnostics growth outside of China.
- Instrument backlog increased due to timing of shipments, leaving some potential upside unrealized in the quarter.
- Signals software business is expected to face difficult year-over-year comparisons, with organic revenue declining approximately 20% in Q2.
- The divestiture of the China immunodiagnostics business is not expected to close until the end of 2027, creating ongoing uncertainty.
Ladies and gentlemen, thank you for joining us, and welcome to the Q2 2026 Revvity earnings conference call. (Operator Instructions)
I will now hand the conference over to Steve Willoughby, Investor Relations. Steve, please go ahead.
Thank you, operator. Good morning, everyone, and welcome to Revvity's second quarter 2026 earnings conference call. On the call with me today are Prahlad Singh, our President and Chief Executive Officer; and Max Krakowiak, our Senior Vice President and Chief Financial Officer.
Before we begin, I'd like to remind you that today's call may include forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from our expectations. Please refer to the safe harbor statements in our earnings release and to our SEC filings for a detailed discussion of these risk factors. We assume no obligation to update these forward-looking statements in the future.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
